Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3- dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery

Nanoscale Research Letters

Volumn 6, Issue , 2011, Pages 1-9

  Chiang, Po Chang ^a   Ran, Yingqing ^a   Chou, Kang Jye ^a   Cui, Yong ^a   Wong, Harvey ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION MODEL; AQUEOUS SOLUBILITY; DISSOLUTION RATES; EPOXIDE HYDROLASES; IN-VIVO; NANO-SUSPENSIONS; PHARMACOKINETIC MODELING; PLASMA PROFILES; SPONTANEOUSLY HYPERTENSIVE RATS; SUBCUTANEOUS ROUTE; SURFACE AREA; SYSTEMIC BLOOD PRESSURE;

BIOCHEMISTRY; BLOOD PRESSURE; DRUG DELIVERY; PHARMACOKINETICS; RATS;

ENZYME INHIBITION;

RATTUS; RODENTIA;

EID: 84856051243     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-6-413     Document Type: Article

References (30)

1. Katoh T, Takahashi K, Capdevila J, Karara A, Falck J, Jacobson H, Badr K: Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol 1991, 261:578-586.
2. Lin W, Falck J, Wong P: Effect of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem Biophys Res Commun 1990, 167:977-981.
3. Imig J, Navar L, Roman R, Reddy K, Falck J: Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996, 7:2364-2370.
4. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin D, Liao J: Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
5. Roman R: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002, 82:131-185.
6. Spector A, Fang X, Snyder G, Weintraub N: Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004, 43:55-90.
7. Imig J: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005, 289:F496-F503.
8. Zhao X, Imig J: Kidney CYP450 enzymes: biological actions beyond drug metabolism. Current Drug Metabolism 2003, 4:73-84.
9. Yu Z, Xu F, Huse L, Morisseau C, Draper A, Newman J, Parker C, Graham L, Engler M, Hammock B, Zeldin D, Kroetz D: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000, 87:992-998.
10. Davis B, David A, Howard L, Morisseau C, Hammock B, Weiss R: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. PNAS 2002, 99:2222-2227.
11. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London) 1993, 362:801-809.
12. Smith K, Pinkerton K, Watanabe T, Pedersen T, Ma S, Hammock B: Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. PNAS 2005, 102:2186-2191.
13. Chiang P, Wahlstrom J, Selbo J, Zhou S, Wene S, Albin L, Warren C, Smith M, Roberds S, Ghosh S, Zhang L, Pretzer D: 1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. J of Exp Nano 2006, 2:239-250.
14. Ghosh S, Chiang P, Wahlstrom J, Fujiwara H, Selbo J, Roberds S: Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol 2008, 102(5):453-458.
15. Wahlstrom J, Chiang P, Ghosh S, Warren C, Wene S, Albin L, Smith M, Roberds S: Pharmacokinetic evaluation of a 1,3-dicyclohexylureananosuspension formulation to support early efficacy assessment. Nanoscale Res Lett 2006, 2:291-296.
16. Bittner B, Mountfield R: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Op Drug Discov Devel 2002, 5(1):59-71.
17. Barrett R: Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004, 3:785-796.
18. Chiang P, Hu Y, Thurston A, Sommers C, Guzova J, Kahn L, Lai Y, Blom J: Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy. J Pharm Sci 2009, 98(11):4354-4364.
19. Liu C: Research and Development of Nanopharmaceuticals in China. Nano Biomed Eng 2009, 1(1):1-18.
20. Liu Y, Miyoshi H, Nakamura M: Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007, 120(12):2527-2537.
21. Urisu T, Wei C: America-Japan Nanomedicine Society (AJNS). Nanomedicine 2006, 2(4):297-298.
22. Liang X, Chen C, Zhao Y, Jia L, Wang P: Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Meta 2008, 9(8):697-709.
23. Si D, Sun Y, Cheng T, Liu C: Biomedical evaluation of nanomedicines. Asian Journal of Pharmacodynamics and Pharmacokinetics 2007, 7(2):83-97.
24. Badyl D, Lata H, Dadhich A: Animal models of hypertension and effect of drugs. Indian J Pharmacol 2003, 35:349-362.
25. Lai Y, Chiang P, Li N, Shevlin K, Brayman T, Hu Y, Selbo J, Hu L: Comparison of in vitro nanoparticles uptake in various cell lines and in vivo pulmonary cellular transport in intratracheally dosed rat model. Nonoscale Res Lett 2008, 3:321-329.
26. Chiang P, South S, Wene S: The impact of dosing interval in a novel tandem oral dosing strategy: enhancing the exposure of low solubility drug candidates in a pre-clinical setting. J Drug Delivery 2011, Article ID 528284, 9 pages.
27. Chiang PC, South SA, Foster KA, Daniels JS, Wene SP, Albin LA, Thompson DC: Utilizing a novel tandem oral dosing strategy to enhance exposure of low solubility drug candidates in pre-clinical setting. J Pharm Sci 2010, 99(7):3132-3140.
28. Oberle R, Chen T, Lloyd C, Barnett J, Owyang C, Meyer J, Amidon G: The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990, 99(5):1275-1282.
29. Chiang P, Kishore N, Thompson D: Combined use of pharmacokinetic modeling and a steady state delivery approach allow early assessment of IκB kinase-2 (IKK-2) target safety and efficacy. J Pharm Sci 2010, 99(3):1278-1287.
30. Kerns E, Di L: Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization Burlington: Elseveir; 2008.